<ul><li>Dublin-based biopharmaceutical company, SynOx, has raised additional funding in the final close of its Series B financing, bringing the total capital raised to €84.8 million.</li><li>The funding round was led by new investor Gilde Healthcare, along with investments from Forbion, HealthCap, and Bioqube Ventures.</li><li>The proceeds will support a Phase 3 clinical trial of emactuzumab, a potential treatment for Tenosynovial Giant Cell Tumour (TGCT), a rare joint disorder.</li><li>The trial, named TANGENT, aims to evaluate the efficacy and safety of emactuzumab, with the first patients already dosed.</li></ul>

Dublin-based SynOx adds new capital to Series B, raising total to €84.8 million

Discover more